|
Patent landscape, scope, and claims: |
Scope of US Patent 8,436,190: What claims cover for bendamustine lyophilized formulation (mannitol + tert-butyl alcohol) and where the real IP leverage sits
US Patent 8,436,190 is claim-focused on a specific pharmaceutical composition for bendamustine (or bendamustine hydrochloride) with defined excipients and concentrations, and on a corresponding lyophilized (freeze-dried) product. The independent claim scope is narrow in ingredients and broad in the “made-from” concept for lyophilization. The key commercial exclusion risk is a competitor’s ability to avoid literal claim coverage by changing excipient identity (mannitol or tertiary-butyl alcohol), excipient concentrations, lyophilization claim hooks, or the stated impurity limit for bendamustine ethylester in the lyophilized product.
What exactly does US 8,436,190 claim for bendamustine (scope of the composition claims)?
Claim 1: Independent composition claim elements (literal scope)
Claim 1 covers a “pharmaceutical composition comprising”:
- bendamustine or bendamustine hydrochloride
- mannitol
- tertiary-butyl alcohol
- water
The claim is structural and excipient-defined: it does not require a particular container, route, or dosage form in Claim 1. It also does not, on its face, require lyophilization in Claim 1.
Practical scope interpretation
- A formulation with the four recited components is within the “comprising” scope even if other excipients are present.
- If a competitor uses a different sugar/polyol (e.g., trehalose, sorbitol) instead of mannitol, Claim 1 can be avoided literally.
- If a competitor uses ethanol, isopropanol, or tert-butanol variants that do not meet “tertiary-butyl alcohol” as claimed, Claim 1 can be avoided literally.
- If the formulation excludes water (for example, a non-aqueous or anhydrous system), it can avoid Claim 1.
Claim 2–3: concentration ranges and a single-point embodiment (higher-risk for generics and “reformulations”)
Claim 2 narrows Claim 1 by concentration ranges:
- bendamustine (or HCl): about 12 to 17 mg/mL
- mannitol: about 20 to 30 mg/mL
- tertiary-butyl alcohol: about 10 to 50% (v/v)
Claim 3 further narrows to a specific formulation point:
- bendamustine (or HCl): about 15 mg/mL
- mannitol: about 25.5 mg/mL
- tertiary-butyl alcohol: about 30% (v/v)
Practical risk
- These ranges create a classic “design space trap.” If an ANDA/505(b)(2) style competitor matches the excipients and runs in the same concentration bands, literal infringement risk rises sharply.
- The use of “about” can enlarge effective coverage beyond exact numeric endpoints, particularly at process development scale where analytical variation exists. The claim still anchors to stated intervals, but it gives room for formulation tolerances.
What does US 8,436,190 protect on lyophilized bendamustine (freeze-dried product scope)?
Claim 4: product claim tied to “made from” the Claim 1 composition
Claim 4 covers:
- A lyophilized pharmaceutical composition made from the composition of Claim 1.
Scope effect
- The claim ties the lyophilized product to the specific starting composition conceptually. It does not add additional excipients to the lyophilized product language.
- Competitors cannot avoid Claim 4 merely by pointing to a dried matrix, because the claim is anchored to the starting formulation composition described in Claim 1.
Design-around lever
- If a lyophilized product is made from a composition that does not meet Claim 1 components (or includes a substituted stabilizer or cosolvent), Claim 4 may be avoided.
Claim 5–6: lyophilized concentration ranges and a second single-point embodiment
Claim 5 incorporates the concentration ranges of Claim 2 into the lyophilized product made from that starting formulation.
- bendamustine (or HCl): about 12 to 17 mg/mL
- mannitol: about 20 to 30 mg/mL
- tertiary-butyl alcohol: about 10 to 50% (v/v)
Claim 6 incorporates the single point of Claim 3 into the lyophilized product:
- bendamustine (or HCl): about 15 mg/mL
- mannitol: about 25.5 mg/mL
- tertiary-butyl alcohol: about 30% (v/v)
Practical risk
- Freeze-dried products often keep the quantitative composition of the pre-lyo solution as the controlling determinant for what is “in said pharmaceutical composition” (depending on claim construction). The concentration language in Claims 5–6 increases risk for formulations that preserve the same loading in the reconstitution-relevant formulation.
What is the impurity limitation in US 8,436,190 and why it matters for infringement?
Claim 7–9: bendamustine ethylester limit in the lyophilized composition
Claims 7–9 add a product-quality constraint:
- The lyophilized composition of the relevant preceding claim
- containing not more than about 0.5% bendamustine ethylester
Claim-specific layering:
- Claim 7 ties the impurity limit to the Claim 4 lyophilized product
- Claim 8 ties it to Claim 5 concentration ranges
- Claim 9 ties it to Claim 6 concentration point
Scope interpretation
- These claims appear to require that the final lyophilized product meets an impurity specification for bendamustine ethylester at or below 0.5%.
- This can create a factual infringement battleground in litigation: analytical testing and method validation become central.
Design-around lever
- A competitor could attempt to reformulate to increase/alter ethylester levels above the threshold. That is commercially unattractive if impurity specs would otherwise need to be controlled for safety/quality, but from a pure claim-avoidance standpoint, it is a lever.
- A competitor can also avoid the earlier excipient/concentration requirements (mannitol and tert-butyl alcohol, and their concentration bands), which would avoid reaching the impurity limitation at all.
How narrow is US 8,436,190 in formulation space?
US 8,436,190 is narrow along three axes and only medium along one axis:
-
Excipient identity axis (narrow):
- Must include mannitol and tertiary-butyl alcohol and water plus bendamustine (or HCl).
-
Loading/cosolvent concentration axis (narrow-to-medium):
- bendamustine: about 12–17 mg/mL (and specifically about 15 mg/mL)
- mannitol: about 20–30 mg/mL (and specifically about 25.5 mg/mL)
- tert-butyl alcohol: about 10–50% v/v (and specifically about 30% v/v)
-
Product form axis (narrow):
- Lyophilized product claims require lyophilization, and the “made from” constraint ties the dried product to the specified starting solution.
-
General “comprising” axis (medium):
- The independent composition uses “comprising,” so additional excipients can exist without taking the formulation outside the claim, as long as the required ingredients and concentrations/ranges are still met for the dependent claims.
What patent landscape surrounds US 8,436,190 for bendamustine lyophilized products in the US?
A complete landscape requires bibliographic and family data (title, assignee, priority, prosecution history, and related continuations/divisionals) plus the Orange Book and citation set (forward and backward). That information is not present in the prompt. Under the constraints for complete and accurate response, no further landscape claims can be asserted.
How strong is US 8,436,190 against generics or 505(b)(2) reformulations?
Strength from claim drafting
- The formulation is defined with specific excipient identities and numeric concentration ranges. That is strong for literal infringement control where a product matches.
- The lyophilized product claims also incorporate concentration ranges, which reduces ambiguity for a competitor that follows the same pre-lyo solution loading.
Weakness from claim quality (litigation leverage)
- The impurity-limit claims (0.5% bendamustine ethylester) add a testable constraint that can be disputed on:
- sampling,
- assay method,
- stability/timepoint,
- batch-to-batch impurity distribution.
- The “about” qualifier creates some flexibility but still keeps the claim tethered to specific numeric intervals.
Highest-risk competitor behavior
- Any competitor matching:
- bendamustine (or HCl),
- mannitol at about 20–30 mg/mL,
- tert-butyl alcohol at about 10–50% (v/v),
- and producing a lyophilized product made from that solution,
- and meeting ethylester at ≤ 0.5%,
faces the highest literal infringement risk.
Claim-by-claim claim map (what a product must have to read on each claim)
| Claim |
Must contain / must be true |
Literal “read-on” trigger |
| 1 |
bendamustine or bendamustine HCl + mannitol + tertiary-butyl alcohol + water |
Any aqueous composition with these four components |
| 2 |
Claim 1 plus bendamustine 12–17 mg/mL, mannitol 20–30 mg/mL, tert-butyl alcohol 10–50% v/v |
Match all three concentration windows |
| 3 |
Claim 1 plus bendamustine ~15 mg/mL, mannitol ~25.5 mg/mL, tert-butyl alcohol ~30% v/v |
Match the specific point (within “about”) |
| 4 |
Lyophilized pharmaceutical composition “made from” Claim 1 composition |
Freeze-dried product derived from the Claim 1 solution |
| 5 |
Claim 4 plus concentrations from Claim 2 |
Lyophilized product derived from the Claim 2 solution |
| 6 |
Claim 4 plus concentrations from Claim 3 |
Lyophilized product derived from the Claim 3 solution |
| 7 |
Claim 4 plus bendamustine ethylester ≤ 0.5% |
Impurity profile meets threshold in the lyophilized product |
| 8 |
Claim 5 plus bendamustine ethylester ≤ 0.5% |
Impurity meets threshold and concentrations match Claim 5 |
| 9 |
Claim 6 plus bendamustine ethylester ≤ 0.5% |
Impurity meets threshold and concentrations match Claim 6 |
Key takeaways
- US 8,436,190 protects a bendamustine (or bendamustine HCl) pharmaceutical composition requiring mannitol + tertiary-butyl alcohol + water, and a lyophilized product made from that composition.
- Dependent claims lock in tight concentration bands (bendamustine 12–17 mg/mL; mannitol 20–30 mg/mL; tert-butyl alcohol 10–50% v/v) and a specific formulation point (15 mg/mL bendamustine; 25.5 mg/mL mannitol; 30% v/v tert-butyl alcohol).
- The most litigation-relevant refinement is the lyophilized impurity cap: ≤0.5% bendamustine ethylester in Claims 7–9.
- The strongest literal infringement path is a competitor product whose pre-lyo formulation and impurity spec match the claimed windows.
FAQs
-
How can a manufacturer design around US 8,436,190 if it wants a lyophilized bendamustine product?
By using a lyophilization feed composition that does not include the claimed excipients (mannitol and/or tertiary-butyl alcohol) or does not fall within the claimed concentration ranges, or by producing a lyophilized product that does not meet the claimed bendamustine ethylester limit (where that claim is asserted).
-
Does US 8,436,190 require a particular dosage form other than lyophilized?
Claim 1 covers a composition in general terms; Claims 4–9 specifically require a lyophilized product made from the claimed composition.
-
Are the concentration limits in US 8,436,190 strict exact values or ranges?
They are expressed as “about” ranges (Claims 2 and 5) and “about” single-point values (Claims 3 and 6), which still anchor coverage to the stated numerical intervals/targets.
-
Which claim is most likely to drive infringement analysis for a freeze-dried bendamustine drug?
Claims 5 and 6 for the concentration-anchored lyophilized product, and Claims 8 and 9 if bendamustine ethylester content is contested.
-
What role does the impurity limit play in determining infringement?
For Claims 7–9, the lyophilized product must contain not more than about 0.5% bendamustine ethylester, which makes analytical testing central to whether the product meets the claim limitation.
References
- US Patent 8,436,190 (claims as provided in prompt).
More… ↓
⤷ Start Trial
|
